Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
2559  Genetic and molecular analysis of tumors of the Nervous system and their coverings Main Campus  Brain
ABBV 131515-791 INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group Main Campus  Brain, Glioblastoma
ABTC 120213-927 Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma Main Campus Phase 1Brain, Glioblastoma
ABTC 1402 15-1529 Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma Main CampusRecurrentPhase 2Brain, Glioblastoma
BRMY 1615 041536C A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy Main Campus Phase 2Brain, Melanoma
CASE 1307296 Ohio Brain Tumor Study (OBTS) Main Campus  Brain
CASE 331313-445 A prospective phase II trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent Glioblastoma Main Campus Phase 2Brain, Glioblastoma
CASE 7113 15-1658 Treatment of Brain Metastases from Breast Cancer with Eribulin Mesylate Main Campus  Brain Metastases from Breast Cancer
CASE 731213-143 Neoadjuvant Radiosurgery for resectable brain metastases: Phase I/II Study Main Campus Phase 1, Phase 2Brain
CASE 7315 16-085 Targeting Myeloid Derived Suppressor Cells in Recurrent Glioblastoma: Phase 0/1 Trial of Low Dose Capecitabine + Bevacizumab in Patients with Recurrent Glioblastoma Main CampusRecurrentPhase 1Brain, Glioblastoma
CASE 831213-221 Dose Escalation for Larger Brain Metastases: Phase I/II Study Main Campus Phase 1, Phase 2Brain
ICT 1315 15-1630 STING (Study of Immunotherapy in Newly Diagnosed Glioblastoma): A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy Main Campus Phase 3Brain, Glioblastoma
INFT 1314 14-831 A Pilot Trial of Intraparenchymally-Administered Topotecan using Convection-Enhanced Delivery (CED) in Patients with Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Requiring Stereotactic Biopsy (IND 117,240) Main CampusStage 3, Stage 4 Brain, Glioblastoma
INFT 1315 15-614 A Pilot Trial of Intraparenchymally-Administered Topotecan using Convection-Enhanced Delivery (CED) in Patients with Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing A Clinically-Indicated Surgical Resection (IND 117,240) Main Campus  Brain, Glioma
NCTG 1310CC00039; N0577 Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma Beachwood, Fairview, Hillcrest, Independence, Main Campus, Wooster Phase 3Brain
NEONC 1315 15-1645 An Open-Label Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma Main CampusRecurrentPhase 1, Phase 2Brain, Glioma
NRG BN001 15-470 Randomized Phase II trial of hypofractionated dose-escalated photon IMRT or proton beam therapy versus conventional photon irradiation with concomitant and adjuvant Temozolomide in patients with newly diagnosed Glioblastoma Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 2Brain, Glioblastoma
NRG CC001 15-1581 A randomized phase III trial of Memantine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases Fairview, Florida Weston, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 3Brain
RPCI 1315 15-536 A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma Main Campus Phase 2Brain, Glioblastoma
STML 131414-698 A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme Main Campus Phase 1, Phase 2Brain, Glioblastoma
12

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.